胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良的临床疗效  

Clinical effect of Weifuchun tablets combined with omeprazole enteric-coated capsules in the treatment of functional dyspepsia

作　　者：康年松 黄戬[2] 钱蓉[3] 谷红苹 韩旭丰 苏文涛 KANG Niansong;HUANG Jian;QIAN Rong;GU Hongping;HAN Xufeng;SU Wentao(Department of Treatment of Disease Department,Yuyao Hospital of Traditional Chinese Medicine,Yuyao,Zhejiang 315400,China;不详)

机构地区：[1]余姚市中医医院治未病科,浙江余姚315400 [2]余姚市人民医院消化内科,浙江余姚315400 [3]余姚市人民医院康复医学科 [4]余姚市中医医院内科 [5]余姚市中医医院中医内科

出　　处：《中华全科医学》2024年第4期597-600,共4页Chinese Journal of General Practice

基　　金：浙江省中青年临床名中医项目(浙中医药[2021]22号);浙江省医学会临床科研基金项目(2020ZYCB05)。

摘　　要：目的探讨胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良患者的临床效果,及其对血清胃蛋白酶原、胃泌素17的影响。方法采用随机数字表法将余姚市中医医院2021年10月—2022年12月收治的128例功能性消化不良患者分为胃复春组与莫沙必利组,每组各64例。莫沙必利组给予奥美拉唑联合莫沙必利片治疗,胃复春组给予奥美拉唑联合胃复春片治疗,连续治疗4周后,比较2组患者的治疗效果、血清胃蛋白酶原、胃泌素17水平等。结果治疗4周后,胃复春组(87.50%,56/64)的治疗总有效率高于莫沙必利组(71.88%,46/64,χ^(2)=4.827,P<0.05);胃复春组胃蛋白酶原Ⅰ[(113.20±10.21)μg/L]水平高于莫沙必利组[(98.26±9.64)μg/L,P<0.05],胃蛋白酶原Ⅱ[(17.21±2.58)μg/L]、胃泌素17[(15.31±2.09)pmol/L]水平均低于莫沙必利组[(20.31±3.11)μg/L、(18.22±2.67)pmol/L,P<0.05]。结论胃复春片联合奥美拉唑肠溶胶囊治疗功能性消化不良患者临床症状改善明显,且能纠正血清胃蛋白酶原、胃泌素17水平的异常,提高患者的预后生活质量。Objective To explore the clinical effect of Weifuchun tablets combined with omeprazole enteric-coated capsules on patients with functional dyspepsia and their influence on serum pepsinogen and gastrin-17 levels.Methods Using a random number table,128 patients diagnosed with functional dyspepsia at Yuyao Hospital of Traditional Chinese Medicine between October 2021 and December 2022 were divided into two groups:Weifuchun group and Mosapride group,eaching consisting of 64 cases.The mosapride group was given a combination of omeprazole and Mosapride tablets,while the Weifuchun group was given a combination of omeprazole and Weifuchun tablets.After 4 weeks of continuous treatment,the therapeutic effect,serum pepsinogen,and gastrin-17 levels were compared between the two groups.Results After 4 weeks of treatment,the Weifuchun group demonstrated a higher total effective rate(87.50%,56/64)compared to the Mosapride group(71.88%,46/64),with a statistically significant difference(χ^(2)=4.827,P<0.05).The Weifuchun group also exhibited higher levels of pepsinogenⅠ[(113.20±10.21)μg/L]compared to the Moxapride group[(98.26±9.64)μg/L,P<0.05].Moreover,the Weifuchun group showed lower levels of pepsinogen Ⅱ[(17.21±2.58)μg/L]and gastrin-17[(15.31±2.09)pmol/L]compared to the Mosapride group[(20.31±3.11)μg/L,(18.22±2.67)pmol/L,P<0.05].Conclusion The combination of Weifuchun tablets and omeprazole entericcoated capsules significantly improves the clinical symptoms of patients with functional dyspepsia.It effectively corrects abnormal levels of serum pepsinogen and gastrin-17,leading to improved prognosis and enhanced quality of life for patients.

关 键 词：功能性消化不良 胃复春片 血清胃蛋白酶原 奥美拉唑 胃泌素17 

分 类 号：R57[医药卫生—消化系统]